Estrella Immunopharma, Inc. (ESLA) Corporate Subsidiaries
Estrella Immunopharma, Inc. (ESLA) is a publicly traded company on the Nasdaq, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: ESLA
CIK: 1844417
Exchange: Nasdaq
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 12/31
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Macias Gini & O'Connell LLP
Auditor SinceSince 6/30/2024 12:00:00 AM
Lead Engagement PartnerMichael Christian
Audit LocationIrvine, California, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 8-K | 2026-09-08 | 2026-09-01 | CURRENT REPORT | 0001213900-26-098123 | View SEC Doc Filr Page |
| 4 | 2026-08-26 | 2026-08-25 | PRIMARY DOCUMENT | 0001996255-26-000004 | View SEC Doc Filr Page |
| 4 | 2026-08-25 | 2026-08-18 | 4 Filing | 0001213900-26-093698 | View SEC Doc Filr Page |
| 8-K | 2026-08-21 | 2026-08-17 | CURRENT REPORT | 0001213900-26-092657 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001172661-26-003573 | View SEC Doc Filr Page |
| 10-Q | 2026-08-13 | 2026-06-30 | QUARTERLY REPORT | 0001213900-26-089215 | View SEC Doc Filr Page |
| 8-K | 2026-06-30 | 2026-06-29 | CURRENT REPORT | 0001213900-26-073847 | View SEC Doc Filr Page |
| DEF 14A | 2026-05-27 | 2026-06-29 | DEF 14A | 0001140361-26-023012 | View SEC Doc Filr Page |
| 10-Q | 2026-05-18 | 2026-03-31 | QUARTERLY REPORT | 0001213900-26-058063 | View SEC Doc Filr Page |
| NT 10-Q | 2026-05-18 | 2026-03-31 | NOTIFICATION OF LATE FILING | 0001213900-26-058062 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-05-15 | — | SCHEDULE 13G Filing | 0001172661-26-002144 | View SEC Doc Filr Page |
| 10-K/A | 2026-04-30 | 2025-12-31 | AMENDMENT NO. 1 TO FORM 10-K | 0001213900-26-050433 | View SEC Doc Filr Page |
| 4 | 2026-04-29 | 2025-09-11 | 4 Filing | 0001213900-26-049602 | View SEC Doc Filr Page |
| 10-K | 2026-03-18 | 2025-12-31 | ANNUAL REPORT | 0001213900-26-029357 | View SEC Doc Filr Page |
| 424B3 | 2026-02-13 | — | PROSPECTUS | 0001213900-26-016605 | View SEC Doc Filr Page |
| EFFECT | 2026-01-23 | — | EFFECT Filing | 9999999995-26-000279 | View SEC Doc Filr Page |
| CORRESP | 2026-01-22 | — | CORRESP Filing | 0001213900-26-006650 | View SEC Doc Filr Page |
| S-1/A | 2026-01-22 | — | REGISTRATION STATEMENT | 0001213900-26-006410 | View SEC Doc Filr Page |
| S-1/A | 2026-01-16 | — | REGISTRATION STATEMENT | 0001213900-26-005233 | View SEC Doc Filr Page |
| 8-K | 2026-01-13 | 2026-01-07 | CURREN REPORT | 0001213900-26-003998 | View SEC Doc Filr Page |
| 8-K | 2026-01-06 | 2026-01-05 | CURRENT REPORT | 0001213900-26-001777 | View SEC Doc Filr Page |
| 424B5 | 2026-01-06 | — | PROSPECTUS SUPPLEMENT | 0001213900-26-001686 | View SEC Doc Filr Page |
| UPLOAD | 2025-12-29 | — | UPLOAD Filing | 0000000000-25-011874 | View SEC Doc Filr Page |
| S-1 | 2025-12-22 | — | REGISTRATION STATEMENT | 0001213900-25-124247 | View SEC Doc Filr Page |
| 8-K | 2025-12-04 | 2025-12-04 | CURRENT REPORT | 0001213900-25-118097 | View SEC Doc Filr Page |